Projected year of payments Projected Year of Payments [Member] Represents projected year of payments. Additions Goodwill, Acquired During Period Statistical Measurement [Domain] Statistical Measurement [Domain] Remaining share repurchase authorization amount Share Repurchase Program, Remaining Authorized, Amount Derivative instruments, notional amount and fair value Derivatives, Fair Value [Line Items] Cover [Abstract] Cover [Abstract] Net change in cash and equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Discount rate Measurement Input, Discount Rate [Member] Schedule of Indefinite-Lived Intangible Assets [Table] Intangible Asset, Indefinite-Lived [Table] Trading Symbol Trading Symbol Fair value hedges Fair Value Hedging [Member] Comprehensive income Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Long-term debt and finance lease obligations Long-Term Debt and Lease Obligation Pension and post-employment benefits Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Fair value - Derivatives in asset position Foreign currency contracts Derivative Asset, Subject to Master Netting Arrangement, before Offset Schedule of basic and diluted earnings per share, impact of two-class method Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Tax benefit Share-Based Payment Arrangement, Expense, Tax Benefit NEW YORK STOCK EXCHANGE, INC. NEW YORK STOCK EXCHANGE, INC. [Member] Cash dividends declared per common share (in dollars per share) Common Stock, Dividends, Per Share, Declared Cash Settled Stock Based Compensation in Connection with Acquisitions Cash Settled Stock Based Compensation in Connection with Acquisitions [Table Text Block] Cash Settled Stock Based Compensation in Connection with Acquisitions Cash flow hedging activities, tax expense (benefit) Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax Accounts receivable Increase (Decrease) in Accounts Receivable Derivative [Table] Derivative [Table] Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Hedging Relationship [Domain] Hedging Relationship [Domain] Summary of amounts and location of derivatives on the condensed consolidated balance sheets Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Proceeds from the exercise of stock options Proceeds from Stock Options Exercised Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Net investment hedges Net Investment Hedging [Member] After-tax compensation expense Share-Based Payment Arrangement, Expense, after Tax Derivative instrument net gains (losses) recognized in the consolidate statements of earnings Derivative, Gain (Loss) on Derivative, Net Sec 2.125 Senior Notes Due 2029 Sec 2.125 Senior Notes Due 2029 [Member] Sec 2.125 Senior Notes Due 2029 Legal Proceedings and Contingencies Legal Matters and Contingencies [Text Block] Portion at fair value measurement Portion at Fair Value Measurement [Member] Aggregate principal amount outstanding Debt and Lease Obligation Duodopa Duodopa [Member] Represents information pertaining to Duodopa, a product of the entity. Number of claims pending Loss Contingency, Pending Claims, Number Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Cash flow hedges Cash Flow Hedging [Member] Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Collaborative and license agreements Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] United States UNITED STATES Inventories Inventory, Net [Abstract] Term loan facilities Loans Payable [Member] Service cost Defined Benefit Plan, Service Cost Other assets Other Assets, Noncurrent Entity Tax Identification Number Entity Tax Identification Number Gross carrying amount Finite-Lived Intangible Assets, Gross Schedule of Finite-Lived Intangible Assets [Table] Intangible Asset, Finite-Lived [Table] Schedule of Long-Term Debt Instruments Schedule of Long-Term Debt Instruments [Table Text Block] Purchases of treasury stock (in shares) Shares repurchased (in shares) Treasury Stock, Shares, Acquired Retirement Plan Type [Axis] Retirement Plan Type [Axis] Accumulated other comprehensive income (loss) AOCI Including Portion Attributable to Noncontrolling Interest [Member] Janssen Biotech Inc. Janssen Biotech Inc [Member] Represents the information pertains to the entity Janssen Biotech Inc. Selling, general and administrative Selling, General and Administrative Expenses [Member] Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities Treasury Stock, Common Treasury Stock, Common [Member] Summary of changes in balances of each component of accumulated other comprehensive loss Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Post-Employment Benefits Postemployment Benefits Disclosure [Text Block] Equity Components [Axis] Equity Components [Axis] Net periodic benefit cost (credit) Defined Benefit Plan, Net Periodic Benefit Cost (Credit) 2.8% senior notes due 2023 Senior Notes Due 2023 At 2.800 Percent [Member] Senior Notes Due 2023 At 2.800 Percent Debt securities Debt Securities, Available-for-Sale Restructuring Type [Axis] Restructuring Type [Axis] Net earnings Business Acquisition, Pro Forma Net Income (Loss) Measurement Frequency [Axis] Measurement Frequency [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Total operating costs and expenses Costs and Expenses Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Investments [Domain] Investments [Domain] Investments Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets Additional paid-in capital Additional Paid in Capital, Common Stock Income tax assets and liabilities, net Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable Entity Small Business Entity Small Business Developed product rights Developed Technology Rights [Member] Geographical [Axis] Geographical [Axis] Other restructuring Other Restructuring Plans [Member] Represents other restructuring plans. Summary of charges associated with integration plan Restructuring and Related Costs [Table Text Block] Payments of Debt Issuance Costs Payments of Debt Issuance Costs Significant unobservable inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Share-based Compensation Arrangement by Share-based Payment Award Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Imbruvica Imbruvica [Member] Represents information pertaining to Imbruvica, a product of the entity. Weighted average Weighted Average [Member] Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Ozurdex Ozurdex [Member] Ozurdex Other long-term liabilities Other Liabilities [Member] Other noncurrent assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Estimated Litigation Liability Estimated Litigation Liability Accumulated goodwill impairment losses Goodwill, Impaired, Accumulated Impairment Loss [Abstract] Credit Facility [Domain] Credit Facility [Domain] Cash and equivalents, beginning of period Cash and equivalents, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Number of individual plaintiff lawsuits Loss Contingency Individual Plaintiff Lawsuits Number Represents the number of individual plaintiff lawsuits filed, pertaining to a loss contingency during the period. Pro Forma Information Business Acquisition, Pro Forma Information [Abstract] Current assets Assets, Current [Abstract] Goodwill Balance at the beginning of the period Balance at the end of the period Goodwill Number of generic companies with whom certain litigation related agreements were entered into Loss Contingency Number of Generic Companies as Counterparty of Litigation Related Agreements Violated Certain Laws Represents the number of generic companies with whom certain litigation related agreements are entered into that violated federal and state antitrust laws and state consumer protection and unjust enrichment laws. Indefinite-Lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Payment for Contingent Consideration Liability, Operating Activities Payment for Contingent Consideration Liability, Operating Activities Share of collaboration development costs responsible by Janssen (as a percent) Collaborative Arrangements Percentage Of Share Of Development Costs Responsible By Third Party Represents the percentage of share in collaboration development costs responsible by Janssen under cost sharing arrangement. Treasury Stock, Common, Shares Treasury Stock, Common, Shares Product and Service [Domain] Product and Service [Domain] Entity Information Entity Information [Line Items] Stock Options Share-Based Payment Arrangement, Option [Member] Short-Term Debt, Weighted Average Interest Rate, over Time Short-Term Debt, Weighted Average Interest Rate, over Time Foreign currency forward exchange contracts Foreign Exchange Forward [Member] Schedule of pre-tax amounts of derivatives designated as net investment hedges recognized in other comprehensive income (loss) Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Changes in the carrying amount of goodwill Goodwill [Roll Forward] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Depreciation Depreciation expense Depreciation Mavyret MAVYRET [Member] Represents information pertaining to MAVYRET, a product of the entity. Other, net Proceeds from (Payments for) Other Financing Activities Comprehensive income attributable to AbbVie Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent Defined benefit plans Pension Plan [Member] Allergan integration plan Allergan Integration Plan [Member] Represents information pertaining to the Allergan integration plan. Cerevel Therapeutics Cerevel Therapeutics [Member] Cerevel Therapeutics Security Exchange Name Security Exchange Name Debt Instrument, Basis Spread on Variable Rate Debt Instrument, Basis Spread on Variable Rate Award Type [Axis] Award Type [Axis] Reclassification out of accumulated other comprehensive loss Reclassification out of Accumulated Other Comprehensive Income [Member] Work-in-process Inventory, Work in Process, Net of Reserves Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Noncontrolling interest Equity, Attributable to Noncontrolling Interest Short-term borrowings Short-Term Debt Dividend Declared 10.26.2023 Dividend Declared 10.26.2023 [Member] Dividend Declared 10.26.2023 Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Weighted average useful life of acquired intangible assets Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Revolving Credit Facility Revolving Credit Facility [Member] Investment, Type [Extensible Enumeration] Investment, Type [Extensible Enumeration] Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Fair Value Measurement Inputs and Valuation Techniques [Abstract] Fair Value Measurement Inputs and Valuation Techniques [Abstract] Product Liability Litigation [Member] Product Liability ALCL Litigation [Member] Product Liability ALCL Litigation Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Sec 2.125 Senior Notes due 2028 Sec 2.125 Senior Notes due 2028 [Member] Sec 2.125 Senior Notes due 2028 [Member] Common stock, issued (in shares) Common Stock, Shares, Issued Foreign currency translation adjustments Goodwill, Other Increase (Decrease) Line of Credit Facility, Maximum Borrowing Capacity Line of Credit Facility, Maximum Borrowing Capacity Concentrations risk (as a percent) Concentration Risk, Percentage Transfers of assets out of Level 3 of the fair value hierarchy Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 Ubrelvy Ubrelvy [Member] Represents information pertaining to Ubrelvy, a product of the entity. Prescription drug abuse litigation in state courts Prescription Drug Abuse Litigation In State Courts [Member] Prescription Drug Abuse Litigation In State Courts Neuroscience Neuroscience [Member] Represents information pertaining to Neuroscience, a key product portfolio of the entity. Long-Term Purchase Commitment, Category of Item Purchased [Domain] Long-Term Purchase Commitment, Category of Item Purchased [Domain] Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property and equipment, gross Property, Plant and Equipment, Gross Long-term debt Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-Term Debt Pre-tax gains (losses) from cash flow hedges recognized in other comprehensive income Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Other Aesthetics Other Aesthetics [Member] Represents information pertaining to Other Aesthetics products. Finite-Lived Intangible Assets, Fair Value Disclosure Finite-Lived Intangible Assets, Fair Value Disclosure Niaspan Niaspan [Member] Represents information pertaining to Niaspan, a product of the entity. Debt and Credit Facilities [Line Items] Debt Instrument [Line Items] Research and development Research and Development Expense [Member] Common stock, authorized (in shares) Common Stock, Shares Authorized Payments to Acquire Businesses, Net of Cash Acquired Payments to Acquire Businesses, Net of Cash Acquired Payments to Acquire Businesses, Net of Cash Acquired Long-Term Debt, Weighted Average Interest Rate, over Time Long-Term Debt, Weighted Average Interest Rate, over Time Probability of payment for royalties excluding approved indications Probability of Payment for Royalties Excluding Approved Indications [Member] Represents estimated probability of payment for royalties excluding approved indications. Weighted-average diluted shares outstanding (in shares) Weighted-average diluted shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Transfers of assets into Level 3 of the fair value hierarchy Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3 Prescription Drug Abuse Litigation In State Courts In process of Being Dismissed Prescription Drug Abuse Litigation In State Courts In process of Being Dismissed [Member] Prescription Drug Abuse Litigation In State Courts In process of Being Dismissed Celsius Therapeutics Celsius Therapeutics [Member] Celsius Therapeutics Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Non-cash litigation reserve adjustments, net of cash payments Non-cash litigation reserve adjustments, net of cash payments Non-cash litigation reserve adjustments, net of cash payments Total stockholders' equity Equity, Attributable to Parent Common stock held in treasury, at cost, 64,310,426 shares as of September 30, 2024 and 57,105,354 as of December 31, 2023 Treasury Stock, Value Collaborations Collaborative Arrangement Disclosure [Text Block] Litigation Case [Axis] Litigation Case [Axis] Business Combinations [Abstract] Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Balance Sheet Location [Axis] Statement of Financial Position Location, Balance [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Deferred income taxes Deferred Income Tax Expense (Benefit) Alphagan/Combigan Alphagan/Combigan [Member] Represents information pertaining to Alphagan/Combigan, a product of the entity. Summary of changes in the carrying amount of goodwill Schedule of Goodwill [Table Text Block] Payments of contingent consideration liabilities Payment for Contingent Consideration Liability, Financing Activities Concentration Risk Type [Domain] Concentration Risk Type [Domain] Other Neuroscience Other Neuroscience [Member] Represents information pertaining to Other Neuroscience products. Botox Therapeutic Botox Therapeutic [Member] Represents information pertaining to Botox Therapeutic, a product of the entity. Schedule of unaudited pro forma combined results Business Acquisition, Pro Forma Information [Table Text Block] Category of Item Purchased [Axis] Category of Item Purchased [Axis] Selling, general and administrative Selling, General and Administrative Expense Fair Value, Recurring Fair Value, Recurring [Member] Accounts receivable, net AbbVie's receivable from Janssen Accounts Receivable, after Allowance for Credit Loss, Current Stock options granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Cost of products sold Cost of Sales [Member] Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net [Abstract] Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net [Abstract] Foreign currency translation adjustments, net of tax expense (benefit) of $25 for the three months and $1 the nine months ended September 30, 2024 and $(17) for the three months and $(11) nine months ended September 30, 2023 Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Document Fiscal Period Focus Document Fiscal Period Focus Exchange [Domain] Exchange [Domain] Acquisition-related expenses Business Combination, Acquisition Related Costs AGN-151607 AGN-151607 [Member] AGN-151607 Effect of dilutive securities (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Balance Sheet Location [Domain] Statement of Financial Position Location, Balance [Domain] Cash per share received by shareholders of acquired company (in dollars per share) Business Acquisition, Share Price Summary of cash activity in the restructuring reserve Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Change in noncontrolling interest Noncontrolling Interest, Period Increase (Decrease) Assets Assets [Abstract] Hematologic Oncology Hematologic Oncology [Member] Represents information pertaining to Hematologic Oncology, a key product portfolio of the entity. Retirement Plan Type [Domain] Retirement Plan Type [Domain] Other comprehensive income (loss) Other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax Document Type Document Type Derivative Contract Type [Domain] Derivative Contract [Domain] Commercial paper Commercial Paper [Member] Pension and post-employment benefits, tax expense (benefit) Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax Amortization of actuarial loss Defined Benefit Plan, Amortization Of Actuarial Gain (Loss), Prior Service Cost (Credit) The amount of amortization of actuarial losses and prior service costs included in the calculation of net periodic pension benefit cost. Purchases of investment securities Payments to Acquire Marketable Securities Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual Net investment hedging activities Accumulated Net Gain (Loss) From Net Investment Hedges [Member] Accumulated Net Gain (Loss) From Net Investment Hedges Prescription drug abuse litigation Prescription Drug Abuse Litigation [Member] Represents information pertaining to prescription drug abuse litigation. Schedule of Defined Benefit Plans Disclosures [Table] Defined Benefit Plan [Table] 5.40% Senior Notes due 2054 5.40% Senior Notes due 2054 [Member] 5.40% Senior Notes due 2054 Short-term borrowings Short-Term Debt, Fair Value Indefinite-lived intangible assets Indefinite-Lived Intangible Assets (Excluding Goodwill) Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Maximum Maximum [Member] Amortization of intangible assets Amortization expense Amortization of Intangible Assets Accumulated goodwill impairment losses Goodwill, Impaired, Accumulated Impairment Loss Other Key Products Other Key Products [Member] Represents information pertaining to other key products of the entity. Net carrying amount Finite-Lived Intangible Assets, Net International Non-US [Member] Investment Type [Axis] Investment Type [Axis] Debt Instrument, Unamortized Discount Debt Instrument, Unamortized Discount Current Fiscal Year End Date Current Fiscal Year End Date Interest Expense, Net Interest Income (Expense), Operating and Nonoperating [Abstract] Licensing, Acquisitions, and Other Arrangements Licensing, Acquisitions, and Other Arrangements Short-term investments Short-Term Investments Statistical Measurement [Axis] Statistical Measurement [Axis] Earnings before income tax expense Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Award Type [Domain] Award Type [Domain] Cash and equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Genentech, Inc. Genentech, Inc. [Member] Genentech, Inc. [Member] Disaggregation of Revenue Disaggregation of Revenue [Line Items] License agreements Licensing Agreements [Member] Stock-based compensation plans and other (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Total assets acquired and liabilities assumed Total assets acquired and liabilities assumed Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized Money market funds and time deposits Investments, Fair Value Disclosure Additional paid-in capital Additional Paid-in Capital [Member] Hedging Relationship [Axis] Hedging Relationship [Axis] Product Liability Other Litigation in State Court Product Liability Other Litigation in State Court [Member] Product Liability Other Litigation in State Court Line of Credit Facility, Expiration Period Line of Credit Facility, Expiration Period Repayments of long-term debt and finance lease obligations Repayment of Long-Term Debt, Long-Term Lease Obligation, and Capital Security Subsequent Event Type [Domain] Subsequent Event Type [Domain] 5.35% Senior Notes due 2044 5.35% Senior Notes due 2044 [Member] 5.35% Senior Notes due 2044 Collaborative arrangement Collaborative Arrangement [Member] Deferred income taxes Deferred income taxes Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Entity Listings, Exchange [Axis] Entity Listings, Exchange [Axis] Short-Term Borrowings [Line Items] Short-Term Debt [Line Items] 4.95% Senior Notes due 2031 4.95% Senior Notes due 2031 [Member] 4.95% Senior Notes due 2031 Amortization of prior service cost (credit) Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Diluted earnings per share (in dollars per share) Earnings Per Share, Diluted Class of Stock [Axis] Class of Stock [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Counterparty Name [Domain] Counterparty Name [Domain] Entity Interactive Data Current Entity Interactive Data Current Type of Restructuring [Domain] Type of Restructuring [Domain] Cash flow hedging activities Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member] Ownership [Axis] Ownership [Axis] Transfers of liabilities into Level 3 of the fair value hierarchy Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 Number of operating segments Number of Operating Segments Net foreign exchange loss (gain) Foreign Currency Transaction Gain (Loss), before Tax Gain (Loss), Foreign Currency Transaction, before Tax Creon Creon [Member] Represents information pertaining to Creon, a product of the entity. Customer [Axis] Customer [Axis] Earnings allocated to participating securities Participating Securities, Distributed and Undistributed Earnings (Loss), Basic Summary of bases used to measure assets and liabilities carried at fair value on a recurring basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Severance and employee benefits Employee Severance [Member] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Business Combination Recognized Identifiable Assets Acquired And Liabilities License Agreements Business Combination Recognized Identifiable Assets Acquired And Liabilities License Agreements Business Combination Recognized Identifiable Assets Acquired And Liabilities License Agreements Restructuring Plans Restructuring and Related Activities Disclosure [Text Block] Significant unobservable input for contingent consideration Business Combination, Contingent Consideration, Liability, Measurement Input Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Net earnings Net earnings Net earnings Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Restructuring costs location [Domain] Restructuring costs location [Domain] Restructuring costs location [Domain] Inventories Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Income tax expense Tax expense (benefit) Income Tax Expense (Benefit) Interest cost Defined Benefit Plan, Interest Cost Stated interest rate (as a percent) Debt Instrument, Interest Rate, Stated Percentage Notional amount of derivative instruments Derivative, Notional Amount Immunology Immunology [Member] Represents information pertaining to Immunology, a key product portfolio of the entity. Interest rate swap contracts Interest Rate Derivative Liabilities, at Fair Value Equity securities Equity Securities, FV-NI Period for recognition of unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Noncurrent, Financing liability Noncurrent, Financing liability Noncurrent, Financing liability Earnings available to common shareholders Net Income (Loss) Available to Common Stockholders, Diluted Net revenues Revenue from Contract with Customer, Excluding Assessed Tax Skyrizi SKYRIZI [Member] Represents information pertaining to SKYRIZI, a product of the entity. AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A) Selling, General And Administrative Expense From Collaborative Arrangements Amount of selling, general and administrative expenses arising from collaborative arrangements, including, but not limited to, profit-sharing, cost-sharing, royalties and other shared costs incurred under the collaboration terms. Summary of pre-tax amounts and location of derivatives recognized in the condensed consolidated statements of earnings Derivative Instruments, Gain (Loss) [Table Text Block] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Effective tax rate Effective Income Tax Rate Reconciliation, Percent Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities Operating earnings Operating Income (Loss) AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Interest expense Interest Expense, Operating and Nonoperating Variable Rate [Domain] Variable Rate [Domain] Business Acquisition Business Acquisition [Line Items] Incurred total cumulative integration charges Restructuring and Related Cost, Cost Incurred to Date Research and development Research and Development Expense (Excluding Acquired in Process Cost) Total liabilities and equity Liabilities and Equity Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Short-term Debt, Type [Domain] Short-Term Debt, Type [Domain] Hedging Designation [Axis] Hedging Designation [Axis] 5.05% Senior Notes due 2034 5.05% Senior Notes due 2034 [Member] 5.05% Senior Notes due 2034 Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Significant amounts reclassified out of each component of AOCI Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) [Line Items] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Interest income Investment Income, Interest Dividends paid Payments of Dividends Interest expense, net Interest expense, net Gains on derivative amount excluded from effectiveness testing Interest Income (Expense), Nonoperating Pre-tax gains (losses) to be transferred into interest expense, net for treasury rate lock agreement cash flow hedges during the next 12 months Treasury Lock Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Treasury Rate Lock Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Current portion of long-term debt and finance lease obligations Long-Term Debt and Lease Obligation, Current Lumigan/Ganfort Lumigan/Ganfort [Member] Represents information pertaining to Lumigan/Ganfort, a product of the entity. Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Measurement Input Type [Axis] Measurement Input Type [Axis] Scenario [Domain] Scenario [Domain] Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,831,415,039 shares issued as of September 30, 2024 and 1,823,046,087 as of December 31, 2023 Common Stock, Value, Outstanding Accumulated other comprehensive loss AOCI Attributable to Parent [Member] Dividend Declared 02.15.2024 Dividend Declared 02.15.2024 [Member] Dividend Declared 02.15.2024 Inventories Inventories Inventory, Net Milestone payments Collaborative Arrangement Milestone Method Payments Receivable The maximum milestone payments that may be received by the entity based on the achievement of specified events under a collaborative arrangement. Product Liability ALCL Litigation in State Court Product Liability ALCL Litigation in State Court [Member] Product Liability ALCL Litigation in State Court Dividends [Domain] Dividends [Domain] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Product and Service [Axis] Product and Service [Axis] Entity Address, State or Province Entity Address, State or Province Statement Statement [Line Items] Measurement Input Type [Domain] Measurement Input Type [Domain] ImmunoGen ImmunoGen [Member] ImmunoGen Aesthetics Aesthetics [Member] Represents information pertaining to Aesthetics, a key product portfolio of the entity. Pfizer License Agreement Member Pfizer License Agreement Member [Member] Pfizer License Agreement Member Defined benefit and other post-employment plans Defined Benefit Plan Disclosure [Line Items] Total identifiable net assets Total identifiable net assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Equity, Class of Treasury Stock Equity, Class of Treasury Stock [Line Items] Senior Notes Due 2023 at 2.850 Percent Senior Notes Due 2023 at 2.850 Percent [Member] Senior Notes Due 2023 at 2.850 Percent Schedule of property and equipment, net Property, Plant and Equipment [Table Text Block] AndroGel antitrust litigation, King Drug Co. of Florence, Inc., et al. v. AbbVie Inc., et al. AndroGel Antitrust Litigation, King Drug Co. of Florence, Inc., et al. v. AbbVie Inc., et al. [Member] Represents information pertaining to AndroGel antitrust litigation filed under King Drug Co. of Florence, Inc., et al. v. AbbVie Inc., et al. Fair market value of awards vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Liabilities and Equity Liabilities and Equity [Abstract] Duration of forward exchange contracts Derivative, Term of Contract Beginning balance Ending balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Summary of net periodic benefit costs relating to the company's defined benefit and other post-employment plans Schedule of Net Benefit Costs [Table Text Block] Financial Instruments and Fair Value Measures Derivatives and Fair Value [Text Block] Post-closing, cash settled expenses related to acquisitions Employee Benefits and Share-Based Compensation Transfers of assets or liabilities between the fair value measurement levels Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net [Abstract] Net investment hedging activities, net of tax expense (benefit) of $(91) for the three months and $(11) for the nine months ended September 30, 2024 and $84 for the three months and $26 nine months ended September 30, 2023 Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), After Reclassification and Tax Amount, after tax and reclassification, of gain (loss) from derivative instruments and nonderivative instruments designated and qualifying as net investment hedge. Charges associated with integration or restructuring plans Restructuring and Related Cost, Incurred Cost Minimum Minimum [Member] Approximate fair value Estimate of Fair Value Measurement [Member] 2.5% Convertible Senior Note 2.5% Convertible Senior Note [Member] 2.5% Convertible Senior Note Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold) Cost of Goods And Services Sold From Collaborative Arrangements Amount of costs of goods and services sold arising from collaborative arrangements, including, but not limited to, profit-sharing, cost-sharing, royalties and other shared costs incurred under the collaboration terms. 4.80% Senior Notes due 2029 4.80% Senior Notes due 2029 [Member] 4.80% Senior Notes due 2029 Juvederm Collection Juvederm Collection [Member] Represents information pertaining to Juvederm Collection, a product of the entity. Concentration Risk [Table] Concentration Risk [Table] Gain (loss) on derivatives Derivative Instruments, Gain (Loss) [Line Items] Foreign currency translation adjustments, tax expense (benefit) Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax Short-term Debt, Type [Axis] Short-Term Debt, Type [Axis] Other long-term liabilities Other long-term liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other Net revenues Business Acquisition, Pro Forma Revenue Approximate length of time over which accumulated gains and losses will be recognized in Cost of products sold Maximum Length of Time Hedged in Cash Flow Hedge U.S. statutory tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Derivative Instrument [Axis] Derivative Instrument [Axis] Global - AbbVie's share of other costs (included in respective line items) Other Expenses From Collaborative Arrangements Amount of other expenses arising from collaborative arrangements, including, but not limited to, profit-sharing, cost-sharing, royalties and other shared costs incurred under the collaboration terms. Supplemental Financial Information Additional Financial Information Disclosure [Text Block] Earnings Per Share Earnings Per Share [Text Block] Schedule of pre-tax amounts of derivatives designated as cash flow hedges recognized in other comprehensive income (loss) Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Subsequent event Subsequent Event [Member] Goodwill and Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Stockholders' equity Equity, Attributable to Parent [Abstract] Intangible assets - In-process research and development Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed In Process Research And Development Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed In Process Research And Development Investments Long-Term Investments Prescription Drug Abuse Litigation brought by States, Counties, Cities and other Municipal Entities Prescription Drug Abuse Litigation brought by States, Counties, Cities and other Municipal Entities [Member] Prescription Drug Abuse Litigation brought by States, Counties, Cities and other Municipal Entities Restructuring Plan [Axis] Restructuring Plan [Axis] Dividend Declared 09.08.2023 Dividend Declared 09.08.2023 [Member] Dividend Declared 09.08.2023 Other Comprehensive Income (Loss), Tax, Parenthetical Disclosures [Abstract] Other Comprehensive Income (Loss), Tax, Parenthetical Disclosure [Abstract] All other Other Products [Member] Represents information pertaining to other products of the entity not specified anywhere. Long-term debt and finance lease obligations, excluding fair value hedges Long Term Debt and Capital Lease Obligations Fair Value Disclosure Represents the fair value amount of as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year from the balance sheet date or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer plus capital lease obligations due to be paid more than one year after the balance sheet date. Cross Currency Swap Contract Cross Currency Swap Contract [Member] Cross Currency Swap Contract Variable Rate [Axis] Variable Rate [Axis] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Entities [Table] Entities [Table] Other expense (income), net Other Nonoperating Income (Expense) Basic EPS Earnings Per Share, Basic, Two Class Method [Abstract] Other post-employment plans Other Postretirement Benefits Plan [Member] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Pre-tax gains (losses) from net investment hedge instruments recognized in other comprehensive income Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Supplemental Financial Information Supplemental Financial Information December 2023 Bridge Credit Facility December 2023 Bridge Credit Facility [Member] December 2023 Bridge Credit Facility Unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Restasis Restasis [Member] Represents information pertaining to Restasis, a product of the entity. Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] Tax court petition Tax court petition [Member] Tax court petition Assets Assets, Fair Value Disclosure [Abstract] Diluted EPS Earnings Per Share, Diluted, Two Class Method [Abstract] Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Cash and equivalents Cash and Cash Equivalents, Fair Value Disclosure Product Liability Other Litigation in Other Countries Product Liability Other Litigation in Other Countries [Member] Product Liability Other Litigation in Other Countries Potential change in unrecognized tax benefits Decrease in Unrecognized Tax Benefits is Reasonably Possible Accounts payable and accrued liabilities AbbVie's payable to Janssen Accounts Payable and Accrued Liabilities, Current Restructuring charges Restructuring Cost and Reserve [Line Items] Local Phone Number Local Phone Number Total intangible assets gross carrying amount Intangible Assets, Gross (Excluding Goodwill) Proceeds from Other Short-Term Debt Proceeds from Other Short-Term Debt Transfers of liabilities out of Level 3 of the fair value hierarchy Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3 Prepaid expenses and other Prepaid Expenses and Other Current Assets [Member] Deferred income taxes Deferred Income Tax Liabilities, Net Floating rate notes due 2023, refinanced Floating Rate Term Loan Tranche Due May 2023, Refinanced [Member] Floating Rate Term Loan Tranche Due May 2023, Refinanced Postemployment Benefits [Abstract] Postemployment Benefits [Abstract] Other Collaboration Arrangements Other Collaboration Arrangements [Member] Represents information relating to the series of other collaborative arrangements. Interest expense, net Interest Expense [Member] Current portion of long-term debt Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-Term Debt Elahere Elahere [Member] Elahere Changes in operating assets and liabilities, net of acquisitions: Increase (Decrease) in Operating Capital [Abstract] Reconciliation of the fair value measurements that use significant unobservable inputs (Level 3) Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Intangible Assets - Developed product rights Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Linzess/Constella Linzess/Constella [Member] Represents information pertaining to Linzess/Constella, a product of the entity. Fair value - Derivatives in liability position Foreign currency contracts Derivative Liability, Subject to Master Netting Arrangement, before Offset Pension and post-employment benefits, net of tax expense (benefit) of $(1) for the three months and $3 for the nine months ended September 30, 2024 and $1 for the three months and $11 for the nine months ended September 30, 2023 Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Current portion of long-term debt and finance lease obligations, excluding fair value hedges Long Term Debt and Capital Lease Obligations Current Fair Value Disclosure Represents the fair value amount of obligation related to long-term debt (excluding convertible debt) and capital leases, the portion which is due in one year or less in the future. Income Statement Location [Axis] Statement of Income Location, Balance [Axis] Share Repurchase Program [Domain] Share Repurchase Program [Domain] FDA Approval FDA Approval [Member] FDA Approval Impairment of Intangible Assets, Finite-Lived Impairment of Intangible Assets, Finite-Lived Common stock Common Stock [Member] Stock-based compensation plans and other Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Epkinly Epkinly [Member] Epkinly Senior Notes Issued in 2024 Senior Notes Issued in 2024 [Member] Senior Notes Issued in 2024 Intangible Assets - Developed product rights Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Developed product rights Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Developed product rights Prepaid expenses and other current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other Business Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of changes in fair value of Level 3 inputs Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Short-term investments Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities Entity Emerging Growth Company Entity Emerging Growth Company Qulipta Qulipta [Member] Qulipta Indefinite-Lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] AbbVie's share of development costs (included in R&D) Research And Development Expense From Collaborative Arrangements Amount of research and development expenses arising from collaborative arrangements, including, but not limited to, profit-sharing, cost-sharing, royalties and other shared costs incurred under the collaboration terms. Total liabilities Liabilities, Fair Value Disclosure Segment Reporting [Abstract] Segment Reporting [Abstract] Entity Central Index Key Entity Central Index Key Scenario [Axis] Scenario [Axis] Schedule of inventories Schedule of Inventory, Current [Table Text Block] Amortization of actuarial losses and other Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax Accounts payable and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Equity Component [Domain] Equity Component [Domain] Debt designated as hedged item in fair value hedges gain (loss) recognized in the consolidated statements of earnings Increase (Decrease) in Fair Value of Hedged Item in Interest Rate Fair Value Hedge Restructuring costs location [Axis] Restructuring costs location [Axis] Restructuring costs location Segment Information Segment Reporting Disclosure [Text Block] Class of Treasury Stock [Table] Class of Treasury Stock [Table] Change in fair value recognized in net earnings Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Adjustments to reconcile net earnings to net cash from operating activities: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Net losses (gains) reclassified from accumulated other comprehensive loss Total reclassifications, net of tax Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Change in fair value of contingent consideration liabilities Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Entity Shell Company Entity Shell Company Measurement Basis [Axis] Measurement Basis [Axis] Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code RSUs and Performance Shares Restricted Stock Units And Performance Shares [Member] Restricted Stock Units And Performance Shares [Member] Prescription Drug Abuse Litigation Covered by a Proposed Class Settlement Prescription Drug Abuse Litigation Covered by a Proposed Class Settlement [Member] Prescription Drug Abuse Litigation Covered by a Proposed Class Settlement Statement [Table] Statement [Table] Research and development milestone expenses Research and Development Milestone Expenses Research and Development Milestone Expenses Foreign currency translation adjustments Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Payable On Funding Agreement Payable On Funding Agreement Payable On Funding Agreement Fair Value Measurement Frequency [Domain] Measurement Frequency [Domain] Counterparty Name [Axis] Counterparty Name [Axis] Geographic risk Geographic Concentration Risk [Member] Comprehensive income attributable to noncontrolling interest Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest City Area Code City Area Code Current liabilities Liabilities, Current [Abstract] Contingent consideration Business Combination, Contingent Consideration, Liability 364-day Term Loan Credit Agreement 364-day Term Loan Credit Agreement [Member] 364-day Term Loan Credit Agreement Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Quoted prices in active markets for identical assets (Level 1) Fair Value, Inputs, Level 1 [Member] Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Total current assets Assets, Current Schedule of interest expense, net Interest Income and Interest Expense Disclosure [Table Text Block] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Senior notes Senior Notes [Member] Rinvoq RINVOQ [Member] Represents information pertaining to RINVOQ, a product of the entity. Dividends Payable [Table] Dividends Payable [Table] Purchases of treasury stock Payments for Repurchase of Common Stock Net revenues attributable to ImmunoGen from acquisition date Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual Long-Term Debt Schedule of Long-Term Debt Instruments [Table] Summary of significant level 3 unobservable inputs Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Weighted-average grant-date fair value of the stock options granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Carrying amount of investments in equity securities that do not have readily determinable fair values Equity Securities without Readily Determinable Fair Value, Amount Restructuring reserve rollforward Restructuring Reserve [Roll Forward] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Collaborative Arrangement, Revenue Not from Contract with Customer, Statement of Income or Comprehensive Income [Extensible Enumeration] Collaborative Arrangement, Revenue Not from Contract with Customer, Statement of Income or Comprehensive Income [Extensible Enumeration] Income Taxes Income Tax Disclosure [Text Block] Per share data Earnings Per Share [Abstract] Raw materials Inventory, Raw Materials, Net of Reserves Accumulated deficit Retained Earnings (Accumulated Deficit) Inventory fair value step-up amortization Amortization of Inventory Fair Value Step-up Represents the amortization expenses of fair value adjustment for acquired inventory. Schedule of the significant amounts reclassified out of each component of accumulated other comprehensive loss Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Other Eye Care Other Eye Care [Member] Represents information pertaining to Other Eye Care products. Botox Cosmetic Botox Cosmetic [Member] Represents information pertaining to Botox Cosmetic, a product of the entity. Class of Stock [Domain] Class of Stock [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Inventories Increase (Decrease) in Inventories Share of collaboration development costs responsible by the entity (as a percent) Collaborative Arrangements Percentage Of Share Of Development Costs Represents the percentage of share in collaboration development costs responsible by the entity under cost sharing arrangement. Debt Issuance Costs, Gross Debt Issuance Costs, Gross Licensing, Acquisitions, and Other Arrangements Acquisitions Collaborations and Other Arrangements Disclosure [Text Block] The entire disclosure for acquisitions, collaborations and other arrangements of the entity. Key Product Portfolio [Axis] Key Product Portfolio [Axis] Information concerning the company's portfolios of key products. Basis of Presentation Organization, Consolidation and Presentation of Financial Statements [Abstract] Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities Key Product Portfolio [Domain] Key Product Portfolio [Domain] [Domain] for Information concerning the company's portfolios of key products. Credit Facility [Axis] Credit Facility [Axis] 5.50% Senior Notes due 2064 5.50% Senior Notes due 2064 [Member] 5.50% Senior Notes due 2064 Dividends declared Dividends, Common Stock, Cash Amendment Flag Amendment Flag Book value Reported Value Measurement [Member] Entity Registrant Name Entity Registrant Name Principal US customers Principal US Customers [Member] Principal US Customers Cash consideration paid to shareholders Payments to Acquire Businesses, Gross Humira H U M I R A [Member] Represents information pertaining to HUMIRA, a product of the entity. Repayments of long-term debt Proceeds from (Repayments of) Long-Term Debt and Capital Securities Accounts receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Aggregate Amount Of Commercial Milestones Payable Aggregate Amount Of Commercial Milestones Payable Aggregate Amount Of Commercial Milestones Payable Other comprehensive income (loss) before reclassifications Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Increase to existing stock repurchase authorization Stock Repurchase Program Increase In Authorized Amount Stock Repurchase Program Increase In Authorized Amount Significant other observable inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Fair Value Measurements Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Repayments of other short-term borrowings Repayments of other short-term borrowings Repayments of Other Short-Term Debt Geographical [Domain] Geographical [Domain] Summary of indefinite-lived intangible assets Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Aggregate principal amount of debt Principal amount of unsecured senior notes Debt Instrument, Face Amount Schedule of worldwide net revenues Disaggregation of Revenue [Table Text Block] Proceeds from Short-Term Debt Proceeds from Short-Term Debt Prepaid expenses and other Prepaid Expense and Other Assets Payments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Entity Address, Postal Zip Code Entity Address, Postal Zip Code Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Summary of share-based compensation expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Amount excluded from the assessment of effectiveness for cash flow hedges Gain (Loss) from Components Excluded from Assessment of Cash Flow Hedge Effectiveness, Net Interest rate swap contracts Interest Rate Swap [Member] Schedule of Restructuring and Related Costs [Table] Restructuring Cost [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Title of 12(b) Security Title of 12(b) Security Concentration Risk Type [Axis] Concentration Risk Type [Axis] Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration] Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration] 1.38% Euro Senior Notes Senior Euro Notes due 2024 at 1.375% [Member] Senior Euro Notes due 2024 at 1.375% Proceeds from (Repayments of) Other Long-Term Debt Proceeds from (Repayments of) Other Long-Term Debt Payments and other adjustments Restructuring Reserve Period Cash Settled and Other Adjustments The change in the restructuring reserve related to the amount of cash paid and other adjustments during the period. Cash and equivalents Cash and Cash Equivalents, at Carrying Value Senior notes due 2027 Senior notes due 2027 [Member] Senior notes due 2027 Other, net Payments for (Proceeds from) Other Investing Activities Other assets Other Noncurrent Assets [Member] CHICAGO STOCK EXCHANGE, INC NYSE CHICAGO, INC. [Member] Tax benefit Reclassification from AOCI, Current Period, Tax Finite-Lived Intangible Assets Finite-Lived Intangible Assets [Line Items] Pre-tax gains (losses) to be transferred into cost of products sold for foreign currency cash flow hedges during the next 12 months Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months Indefinite-Lived Intangible Assets [Line Items] Indefinite-Lived Intangible Assets [Line Items] Impairment of intangible assets Impairment of Intangible Assets (Excluding Goodwill) Dividend Declared 06.21.24 Dividend Declared 06.21.24 [Member] Dividend Declared 06.21.24 Concentration of Risk Concentration Risk [Line Items] Sales and maturities of investment securities Proceeds from Sale, Maturity and Collection of Investments Fair Value Measurement [Domain] Fair Value Measurement [Domain] Probability of payment for royalties by indication Probability of Payment for Royalties by Indication [Member] Represents probability of payment for royalties by indication. Basic earnings per share (in dollars per share) Earnings Per Share, Basic Short-Term Borrowings [Table] Short-Term Debt [Table] Ownership [Domain] Ownership [Domain] Acquired IPR&D and milestones Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation, Writeoff Dividends Payable Dividends Payable [Line Items] Designated as hedging instrument Designated as Hedging Instrument [Member] Earnings available to common shareholders Net Income (Loss) Available to Common Stockholders, Basic Total current liabilities Liabilities, Current Share Repurchase Program [Axis] Share Repurchase Program [Axis] Unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Total assets Assets Schedule of profit and cost sharing relationship Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Cost of products sold Losses (gains) on foreign currency forward exchange contracts Cost of Goods and Services Sold Long-Term Line of Credit Long-Term Line of Credit Shares granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Dividend Declared 09.06.24 Dividend Declared 09.06.24 [Member] Dividend Declared 09.06.24 Acquisitions of property and equipment Payments to Acquire Property, Plant, and Equipment Other long-term liabilities Other Liabilities, Noncurrent Sec 2.625 Senior Notes Due 2028 Sec 2.625 Senior Notes Due 2028 [Member] Sec 2.625 Senior Notes Due 2028 Commitments and contingencies Commitments and Contingencies Fair value step-up adjustment to inventories Business Combination, Fair Value Adjustment to Inventories Represents fair value step-up adjustments to inventories as of acquisition date. Net investment hedging activities AOCI, Derivative Qualifying as Hedge, Excluded Component, Parent [Member] Accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities [Member] Number of principal customers Number of Principal US Customers Represents the number of principal U.S. customers of the entity. Summary of quarterly cash dividends Schedule of Dividends Payable [Table Text Block] Repayments of Short-Term Debt Repayments of Short-Term Debt Fair value, asset and liability measures Bases used to measure the approximate fair values of the financial instruments Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Net revenues Total net revenues Revenues Equity Share-Based Payment Arrangement [Text Block] Vraylar Vraylar [Member] Represents information pertaining to Vraylar, a product of the entity. Not designated as hedging instrument Not designated as hedges Not Designated as Hedging Instrument [Member] Entity Address, City or Town Entity Address, City or Town Proceeds from issuance of long-term debt Proceeds from Issuance of Long-Term Debt Schedule of fair value of assets acquired and liabilities assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Dividend Declared 06.22.2023 Dividend Declared 06.22.2023 [Member] Dividend Declared 06.22.2023 Debt Instrument [Axis] Debt Instrument [Axis] Collaborative Arrangements [Abstract] Collaborative Arrangements [Abstract] Collaborative Arrangements Dividends [Axis] Dividends [Axis] Pre-tax compensation expense Share-Based Payment Arrangement, Expense International - AbbVie's share of profits (included in net revenues) Collaboration revenues Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer Net earnings attributable to AbbVie Inc. Net earnings attributable to AbbVie Inc. Total reclassifications, net of tax Net Income (Loss) Attributable to Parent Other operating income Other Operating Income (Expense), Net Schedule of book values, approximate fair values and bases used to measure certain financial instruments Fair Value, by Balance Sheet Grouping [Table Text Block] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract] Sec 0.750 Senior Notes Due 2027 Sec 0.750 Senior Notes Due 2027 [Member] Sec 0.750 Senior Notes Due 2027 [Member] Loss Contingencies [Table] Loss Contingencies [Table] Business Acquisition [Axis] Business Acquisition [Axis] Summary of definite-lived intangible assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Property and Equipment Property, Plant and Equipment, Net [Abstract] Entity File Number Entity File Number Liabilities Liabilities, Fair Value Disclosure [Abstract] Cash flow hedging activities, net of tax expense (benefit) of $(8) for the three months and $(3) for the nine months ended September 30, 2024 and $7 for the three months and $(1) for the nine months ended September 30, 2023 Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Document Fiscal Year Focus Document Fiscal Year Focus Noncontrolling interest Noncontrolling Interest [Member] Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Purchases of treasury stock Payment for shares repurchased Treasury Stock, Value, Acquired, Cost Method Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Effect of exchange rate changes on cash and equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Total assets Assets, Fair Value Disclosure Restructuring Plan [Domain] Restructuring Plan [Domain] Document Period End Date Document Period End Date Schedule of Research and Development Assets Acquired Other than Through Business Combination Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation [Table Text Block] Finished goods Inventory, Finished Goods, Net of Reserves Other, net Other Noncash Income (Expense) December 2018 Stock Repurchase Authorization December 2018 Stock Repurchase Authorization [Member] December 2018 Stock Repurchase Authorization December 2023 Term Loan Credit Agreement December 2023 Term Loan Credit Agreement [Member] December 2023 Term Loan Credit Agreement Senior Euro Notes Due 2024 At 1.250 Percent [Member] Senior Euro Notes Due 2024 At 1.250 Percent [Member] Senior Euro Notes Due 2024 At 1.250 Percent Product Liability Other Litigation Product Liability Other Litigation [Member] Product Liability Other Litigation Senior Euro Notes Due 2024 At 3.85 percent Senior Euro Notes Due 2024 At 3.85 percent [Member] Senior Euro Notes Due 2024 At 3.85 Percent Accounts payable and accrued liabilities Accounts payable and accrued liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Accounts receivable, net Accounts Receivable [Member] Net earnings attributable to noncontrolling interest Net Income (Loss) Attributable to Noncontrolling Interest Foreign currency contracts Foreign Exchange Contract [Member] Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Other acquisitions and investments Cash outflows related to acquisitions and investments Payments to Acquire Other Investments Litigation Case Type [Domain] Litigation Case [Domain] Dividend Declared 02.16.23 Dividend Declared 02.16.23 [Member] Dividend Declared 02.16.23 Customer [Domain] Customer [Domain] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Retained earnings Retained Earnings [Member] Weighted-average basic shares outstanding (in shares) Weighted-average basic shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Venclexta VENCLEXTA [Member] Represents information pertaining to VENCLEXTA, a product of the entity. Sec 1.250 Senior Notes due 2031 Sec 1.250 Senior Notes due 2031 [Member] Sec 1.250 Senior Notes due 2031 [Member] Intangible assets, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets Total equity Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Property and equipment, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Product Liability ALCL Litigation in Other Countries Product Liability ALCL Litigation in Other Countries [Member] Product Liability ALCL Litigation in Other Countries Eye Care Eye Care [Member] Represents information pertaining to Eye Care, a key product portfolio of the entity. Restructuring charges Restructuring Reserve Cash Settled Restructuring Gains (Losses) The change in the restructuring reserve related to the amount of restructuring gains (losses) during the period that are expected to be cash settled. Earnings allocated to participating securities Participating Securities, Distributed and Undistributed Earnings (Loss), Diluted Treasury rate lock agreements Treasury Lock [Member] Net investment hedging activities, tax expense (benefit) Other Comprehensive Income (Loss), Net Investment Hedge, Tax Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on derivative instruments and nonderivative instruments designated and qualifying as net investment hedge. Entity Filer Category Entity Filer Category Amount excluded from the assessment of effectiveness for fair value hedges Gain (Loss) from Components Excluded from Assessment of Fair Value Hedge Effectiveness, Net Accrued balance beginning of the period Accrued balance end of the period Restructuring Reserve Income Statement Location [Domain] Statement of Income Location, Balance [Domain] Legal Proceedings and Contingencies Loss Contingencies [Line Items] Money Market Funds [Member]